163 related articles for article (PubMed ID: 27188717)
1. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M
J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717
[TBL] [Abstract][Full Text] [Related]
2. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
[TBL] [Abstract][Full Text] [Related]
3. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
4. Artificial neural network classifier predicts neuroblastoma patients' outcome.
Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
[TBL] [Abstract][Full Text] [Related]
5. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
6. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
7. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
9. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J
Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
13. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
14. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.
Meng X; Feng C; Fang E; Feng J; Zhao X
J Cell Mol Med; 2020 Sep; 24(18):10367-10381. PubMed ID: 32683778
[TBL] [Abstract][Full Text] [Related]
16. A three-gene expression signature model for risk stratification of patients with neuroblastoma.
Garcia I; Mayol G; Ríos J; Domenech G; Cheung NK; Oberthuer A; Fischer M; Maris JM; Brodeur GM; Hero B; Rodríguez E; Suñol M; Galvan P; de Torres C; Mora J; Lavarino C
Clin Cancer Res; 2012 Apr; 18(7):2012-23. PubMed ID: 22328561
[TBL] [Abstract][Full Text] [Related]
17. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of the functions and prognostic values of RNA-binding proteins in neuroblastoma.
Yang J; Zhou J; Li C; Wang S
PLoS One; 2021; 16(12):e0260876. PubMed ID: 34879089
[TBL] [Abstract][Full Text] [Related]
19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
20. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
